Treatment of allogeneric stem cell transplantation on renal cell carcinotes: Recent progress

Chinese Journal of Cancer Biotherapy

Volumn 15, Issue 1, 2008, Pages 95-98

  Wang, Xi You ^a   Yang, Yong ^a   Hong, Bao Fa ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; KIDNEY CARCINOMA; MAJOR HISTOCOMPATIBILITY COMPLEX; METASTASIS; REVIEW;

EID: 60649107698     PISSN: 1007385X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Schrader AJ, Varga Z, Hegele A, et al. Second-line strategies for metastatic renal cell carcinoma: classics and novel approaches [J]. J Cancer Res Clin Oncol, 2006, 132(3): 137-149.
2. van Spronsen DJ, de Weijer KJ, Mulders PF, et al. Novel treatment strategies in clear-cell metastatic renal cell carcinoma [J]. Anticancer Drugs. 2005,16(7):709-717.
3. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma[J]. J Clin Oncol, 2006, 24(1): 16-24.
4. Hainsworth JD, Sosman JA, Spigel DR, et al. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib[J]. J Clin Oncol, 2005, 23(31): 7889-7896.
5. Eibl B, Schwaighofer H, Nachbaur D, et al. Evidence for a graft-versustumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer[J]. Blood, 1996, 88(4): 1501-1508.
6. Storb RF, Lucarelli G, Mc Sweeney PA, et al. Hematopoietic cell transplantation for benign hematological disorders and solid tumors [J]. Hematology, 2003, 372-397.
7. Diaconescu R, Flowers CR, Storer B, et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors [J]. Blood, 2004, 104(5), 1550-1558.
8. Mc Sweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects[J]. Blood, 2001, 97(11): 3390-3400.
9. Ueno NT, Cheng YC, Rondon G, et al. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors[J]. Blood, 2003, 102(10):3829-3836.
10. Rini BI, Zimmerman T, Stadler WM, et al. Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results[J]. J Clin Oncol, 2002, 20(8): 2017-2024.
11. Pedrazzoli P, Da Prada GA, Giorgiani G, et al. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies[J]. Cancer, 2002, 94(9): 2409-2415.
12. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation [J]. N Engl J Med, 2000, 343 (11): 750-758.
13. Peccatori J, Barkholt L, Demirer T, et al. Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation[J]. Cancer, 2005, 104(10): 2099-2103.
14. Rini BI, Halabi S, Barrier R, et al. Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB Intergroup Phase II Study[J]. Biol Blood Marrow Transplant, 2006, 12(17): 778-785.
15. Horwitz ME, Barrett AJ, Brown MR, et al. Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft [J]. N Engl J Med, 2001, 344(12): 881-888.
16. Klangsinsirikul P, Carter GI, Byrne JL, et al. Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution[J]. Blood, 2002, 99(7): 2586-2591.
17. Garderet L, Snell V, Przepiorka D, et al. Effective depletion of alloreactive lymphocytes from peripheral blood mononuclear cell preparations[J]. Transplantation, 1999, 67(1): 124-130.
18. Zoller M. Tumor vaccination after allogeneic bone marrow cell reconstitution of the nonmyeloablatively conditioned tumor-bearing murine host[J]. J Immunol, 2003, 171(12): 6941-6953.
19. Cohen JL, Boyer O, Klatzmann D, et al. Suicide gene therapy of graft-versus-host disease: immune reconstitution with transplanted mature T cells[J]. Blood, 2001, 98(7): 2071-2076.
20. Litvinova E, Maury S, Boyer O, et al. Graft-versus-leukemia effect after suicide-gene-mediated control of graft-versus-host disease. [J] Blood, 2002, 100(6): 2020-2025.
21. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants[J]. Science, 2002, 295(5562): 2097-2100.
22. Rossi S, Blazar BR, Farrell CL, et al. Keratinocyte growth factor preserves normal thymopoiesis and thymic microenvironment during experimental graft-versus-host disease[J]. Blood, 2002, 100(2): 682-691.
23. Lewin SR, Heller G, Zhang L, et al. Direct evidence for new T-cell generation by patients after either T-cell-depleted or unmodified allogeneic hematopoietic stem cell transplantations. [J] Blood, 2002, 100(6): 2235-2242.
24. Anderson LD, Petropoulos D, Everse LA, et al. Enhancement of graft-versus-tumor activity and graft-versus-host disease by pretransplant immunization of allogeneic bone marrow donors with a recipient-derived tumor cell vaccine [J]. Cancer Res, 1999, 59 (7): 1525-1530.
25. Teshima T, Mach N, Hill GR, et al. Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation[J]. Cancer Res, 2001, 61(1): 162-171.
26. Barkholt L, Bregni M, Remberger M, et al. Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe[J]. Ann Oncol, 2006, 17(7):1134-1140.
27. Harano M, Eto M, Iwai T, et al. Renal cancer treatment with low levels of mixed chimerism induced by nonmyeloablative regimen using cyclophosphamide in mice [J]. Cancer Res, 2005, 65 (21): 10032-10040.
28. + IFN-gamma producing T cells [J]. Bone Marrow Transplant, 2004, 33 (5): 491-497.
29. Dansey RD, Baynes RD. Nonablative allogeneic hematopoietic stem cell transplantation [J]. Curr Opin Oncol, 2001, 13(1): 27-32.
30. Blaise D, Bay JO, Faucher C, et al. Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors [J]. Blood, 2004, 103(2): 435-441.
31. Takahashi Y, Childs RW. Nonmyeloablative transplantation: an allogeneic-based immunotherapy for renal cell carcinoma[J]. Clin Cancer Res, 2004, 10(18 Pt 2): 6353S-63539S.
32. Drachenberg D, Childs RW. Allogeneic stem cell transplantation as immunotherapy for renal cell carcinoma: from immune enhancement to immune replacement[J]. Urol Clin North Am, 2003, 30 (3):611-622.